Phillips 66 Total Cost of Revenue increased by 0.3% to $29.22B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.6%, from $27.66B to $29.22B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows an upward trend with a 3.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
total_cost_of_revenue| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.22B | $27.53B | $29.29B | $33.50B | $42.65B | $38.65B | $35.15B | $29.34B | $30.57B | $34.33B | $33.84B | $32.39B | $34.63B | $32.19B | $30.75B | $27.66B | $29.08B | $30.22B | $29.14B | $29.22B |
| QoQ Change | — | +9.2% | +6.4% | +14.4% | +27.3% | -9.4% | -9.1% | -16.5% | +4.2% | +12.3% | -1.4% | -4.3% | +6.9% | -7.0% | -4.5% | -10.1% | +5.1% | +3.9% | -3.6% | +0.3% |
| YoY Change | — | — | — | — | +69.1% | +40.4% | +20.0% | -12.4% | -28.3% | -11.2% | -3.7% | +10.4% | +13.3% | -6.2% | -9.1% | -14.6% | -16.0% | -6.1% | -5.3% | +5.6% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Refining | $15.03B | $16.96B | $17.44B | $18.34B | $20.73B |
| Midstream | $4.09B | $3.51B | $3.58B | $4.04B | $4.11B |
| Renewable Fuels | $1.54B | $1.63B | $1.53B | $1.40B | $1.50B |
| Chemicals | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| M&S | $19.05B | — | — | — | — |
| Total | $27.66B | $29.08B | $30.22B | $29.14B | $29.22B |